Literature DB >> 2908048

Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats.

P M Klockowski1, G Levy.   

Abstract

The purpose of this investigation was to determine the relative contribution of diazepam and its active metabolites (desmethyldiazepam, oxazepam and temazepam) to the hypnotic activity of this benzodiazepine drug and to assess the role of rate of drug administration as a determinant of the relative concentrations of diazepam and its active metabolites in serum and in the central nervous system at the onset of a predefined pharmacologic endpoint. Rats were given i.v. infusions of diazepam to onset of loss of righting reflex. Samples of cerebrospinal fluid (CSF), blood (for serum) and brain were obtained at that time and were analyzed for diazepam and its active metabolites. Based on the results of six experiments on groups of 6 to 14 rats performed at the same time of day over 11 months, the pharmacologic response of the animals was found to be relatively consistent, with little variation between rats and between experiments in body weight-normalized effective dose and in diazepam serum and CSF concentrations. All three active metabolites of diazepam were found in serum, CSF and brain; they were relatively more prominent in CSF than in serum. Variation of the diazepam infusion rate (four rates between 0.10 and 0.34 mg/min per approximately 200-g rat) was associated with changes in average onset time (50 to 10 min) and dose (26 to 17 mg/kg) required to produce the pharmacologic effect. The drug and metabolite concentrations in CSF determined in these experiments, together with corresponding concentrations obtained by infusion of each active metabolite individually, yielded estimates of their relative hypnotic potency that were unaffected by differences in serum protein binding and tissue distribution.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908048

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats.

Authors:  A Delon; L M Levasseur; M Giraudon; S Bouquet; W Couet
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 2.  Modulation and polytypic signaling in GABAergic transmission.

Authors:  J L Schlichting
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

3.  A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain.

Authors:  X Tong; P N Patsalos
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.

Authors:  J Semba; G Curzon; P N Patsalos
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Kinetics of drug action in disease states. XXXI. Effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine (oxazepam) in rats.

Authors:  J S Walker; P M Klockowski; G Levy
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

6.  Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam.

Authors:  D J Greenblatt; V H Sethy
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  A new approach for early assessment of the epileptogenic potential of quinolones.

Authors:  A Delon; C Pariat; P Courtois; S Bouquet; W Couet
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 8.  On the rate and extent of drug delivery to the brain.

Authors:  Margareta Hammarlund-Udenaes; Markus Fridén; Stina Syvänen; Anubha Gupta
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

9.  Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat.

Authors:  S Nagaki; N Ratnaraj; P N Patsalos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

10.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.